Bayer enters a defining week as two parallel tracks converge: a US Supreme Court hearing on Monday that could reshape its glyphosate litigation landscape, and shareholder approval for a €7 billion capital buffer to fund potential settlements. The Leverkusen-based conglomerate is simultaneously fighting a legal rear-guard action and preparing for financial firepower.
A Capital Buffer with Conditions
At Friday’s virtual annual general meeting, shareholders gave the green light to a precautionary capital authorization by a narrow 59.42% majority. CEO Bill Anderson can now issue new shares worth up to €7 billion at any time, though management has stressed no immediate capital increase is planned. The move is widely interpreted as a signal of readiness to negotiate broad settlements rather than an imminent equity raise.
The authorization sits alongside a separate $7 billion-plus settlement package that has already received preliminary court approval. Claimants have until early June to opt out of that arrangement, creating a tight deadline for final resolution.
Supreme Court Pivot Point
Monday’s oral arguments before the US Supreme Court in the Durnell case represent the most significant legal event for Bayer since the glyphosate crisis erupted. The company argues that federal law—specifically EPA labeling requirements—should preempt state-level failure-to-warn claims. The US Department of Justice has sided with Bayer’s position.
A ruling in Bayer’s favor, expected by the end of June, would strip the legal foundation from thousands of pending and future lawsuits. An adverse outcome, however, could expose the company to an even larger wave of litigation and potentially inflate settlement costs beyond current provisions.
Cash Flow Squeeze Intensifies
The legal overhang is taking a heavy toll on Bayer’s finances. For the current fiscal year, management projects revenue of up to €47 billion but expects free cash flow to remain deeply negative. The culprit: anticipated payouts of roughly €5 billion for ongoing litigation.
Should investors sell immediately? Or is it worth buying Bayer?
To preserve liquidity, Bayer is paying only the statutory minimum dividend for the past year—€0.11 per share, yielding a meager 0.29%. The stock trades ex-dividend on Monday, adding a technical drag to an already weak chart. Shares closed Friday at €38.50, down roughly 6% on the week and slipping back below the 50-day moving average of €40.50.
Despite the recent pullback, Bayer’s stock has rallied about 71% year-to-date, reflecting optimism that the legal overhang may be nearing resolution. Barclays analysts maintain an overweight rating with a €48 price target.
Pipeline Progress Offers a Glimmer
Amid the legal and financial turbulence, Bayer’s pharmaceuticals division delivered encouraging news. The blood thinner Asundexian reduced ischemic strokes by 26% versus placebo in the OCEANIC-STROKE study, without an elevated bleeding risk. The FDA subsequently granted the drug Fast Track designation, accelerating its path to potential approval.
Leadership Continuity
The supervisory board is betting on stability to navigate the crisis. Anderson’s contract was extended through spring 2029 at the AGM, while pharma chief Stefan Oelrich remains in place. In finance, Judith Hartmann will take the helm from Wolfgang Nickl at the end of May.
The next major catalyst arrives on May 12, when Bayer reports first-quarter results. Until then, all eyes remain on Washington and the Supreme Court’s gavel.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from April 26 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 26.
Bayer: Buy or sell? Read more here...
